How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
45
APLS Quote, Financials, Valuation and Earnings
Last price:
$23.45
Seasonality move
:
10.16%
Day range:
$22.14 - $23.79
52-week range:
$16.10 - $30.60
Dividend yield:
0%
P/E ratio:
77.68x
P/S ratio:
2.87x
P/B ratio:
7.28x
Volume:
5.7M
Avg. volume:
2.8M
1-year change:
-21.21%
Market cap:
$2.9B
Revenue:
$781.4M
EPS (TTM):
$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
APLS
Apellis Pharmaceuticals, Inc.
|
$199.3M | -$0.39 | 14.71% | -34.55% | $33.95 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 111.57% | -58.59% | $485.76 |
|
FBIO
Fortress Biotech, Inc.
|
$26.2M | -$0.31 | 73.08% | -72.5% | $10.75 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.16 | 29.62% | 234.42% | $14.50 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$153.6M | -$1.25 | 45.76% | -35.54% | $90.67 |
|
SRPT
Sarepta Therapeutics, Inc.
|
$389.1M | -$0.78 | -49.56% | -91.57% | $21.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
APLS
Apellis Pharmaceuticals, Inc.
|
$23.07 | $33.95 | $2.9B | 77.68x | $0.00 | 0% | 2.87x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$349.58 | $485.76 | $46.2B | 1,453.56x | $0.00 | 0% | 14.34x |
|
FBIO
Fortress Biotech, Inc.
|
$3.38 | $10.75 | $104.9M | -- | $0.00 | 0% | 1.59x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.28 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.31x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$81.92 | $90.67 | $13.3B | -- | $0.00 | 0% | 13.95x |
|
SRPT
Sarepta Therapeutics, Inc.
|
$21.31 | $21.43 | $2.2B | 20.50x | $0.00 | 0% | 0.91x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
APLS
Apellis Pharmaceuticals, Inc.
|
54.23% | 0.559 | 16.61% | 2.96x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.206 | 4.61% | 2.37x |
|
FBIO
Fortress Biotech, Inc.
|
55.01% | 0.594 | 55.12% | 1.93x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.510 | 19.43% | 2.51x |
|
SRPT
Sarepta Therapeutics, Inc.
|
48.64% | -0.411 | 61.92% | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
APLS
Apellis Pharmaceuticals, Inc.
|
$433.7M | $223.2M | 6.35% | 18.94% | 48.67% | $108.3M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
FBIO
Fortress Biotech, Inc.
|
$10.7M | -$6.8M | -56.09% | -223.06% | -38.63% | -$6.1M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
SRPT
Sarepta Therapeutics, Inc.
|
$230.1M | -$62.9M | -10.24% | -20.67% | -15.75% | -$55.6M |
Apellis Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns APLS or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of 20.1%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About APLS or ALNY?
Apellis Pharmaceuticals, Inc. has a consensus price target of $33.95, signalling upside risk potential of 47.15%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $485.76 which suggests that it could grow by 38.96%. Given that Apellis Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Apellis Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APLSApellis Pharmaceuticals, Inc.11 7 1 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is APLS or ALNY More Risky?
Apellis Pharmaceuticals, Inc. has a beta of 0.305, which suggesting that the stock is 69.48% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.539%.
-
Which is a Better Dividend Stock APLS or ALNY?
Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APLS or ALNY?
Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 77.68x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,453.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 2.87x versus 14.34x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APLSApellis Pharmaceuticals, Inc.2.87x 77.68x $458.6M $215.7M ALNYAlnylam Pharmaceuticals, Inc.14.34x 1,453.56x $1.2B $251.1M
-
Which has Higher Returns APLS or FBIO?
Fortress Biotech, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of 50.07%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Fortress Biotech, Inc.'s return on equity of -223.06%.
Company Gross Margin Earnings Per Share Invested Capital APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M FBIOFortress Biotech, Inc.60.8% $0.11 $133.5M -
What do Analysts Say About APLS or FBIO?
Apellis Pharmaceuticals, Inc. has a consensus price target of $33.95, signalling upside risk potential of 47.15%. On the other hand Fortress Biotech, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 218.05%. Given that Fortress Biotech, Inc. has higher upside potential than Apellis Pharmaceuticals, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Apellis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APLSApellis Pharmaceuticals, Inc.11 7 1 FBIOFortress Biotech, Inc.2 0 0 -
Is APLS or FBIO More Risky?
Apellis Pharmaceuticals, Inc. has a beta of 0.305, which suggesting that the stock is 69.48% less volatile than S&P 500. In comparison Fortress Biotech, Inc. has a beta of 1.423, suggesting its more volatile than the S&P 500 by 42.327%.
-
Which is a Better Dividend Stock APLS or FBIO?
Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Fortress Biotech, Inc. pays out 3.9% of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios APLS or FBIO?
Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are larger than Fortress Biotech, Inc. quarterly revenues of $17.6M. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Fortress Biotech, Inc.'s net income of $8.8M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 77.68x while Fortress Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 2.87x versus 1.59x for Fortress Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APLSApellis Pharmaceuticals, Inc.2.87x 77.68x $458.6M $215.7M FBIOFortress Biotech, Inc.1.59x -- $17.6M $8.8M
-
Which has Higher Returns APLS or FOLD?
Amicus Therapeutics, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of 10.24%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About APLS or FOLD?
Apellis Pharmaceuticals, Inc. has a consensus price target of $33.95, signalling upside risk potential of 47.15%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.54%. Given that Apellis Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Apellis Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APLSApellis Pharmaceuticals, Inc.11 7 1 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is APLS or FOLD More Risky?
Apellis Pharmaceuticals, Inc. has a beta of 0.305, which suggesting that the stock is 69.48% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock APLS or FOLD?
Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APLS or FOLD?
Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 77.68x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 2.87x versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APLSApellis Pharmaceuticals, Inc.2.87x 77.68x $458.6M $215.7M FOLDAmicus Therapeutics, Inc.7.31x -- $169.1M $17.3M
-
Which has Higher Returns APLS or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of -82.06%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About APLS or IONS?
Apellis Pharmaceuticals, Inc. has a consensus price target of $33.95, signalling upside risk potential of 47.15%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.67 which suggests that it could grow by 10.68%. Given that Apellis Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Apellis Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APLSApellis Pharmaceuticals, Inc.11 7 1 IONSIonis Pharmaceuticals, Inc.10 6 0 -
Is APLS or IONS More Risky?
Apellis Pharmaceuticals, Inc. has a beta of 0.305, which suggesting that the stock is 69.48% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.158%.
-
Which is a Better Dividend Stock APLS or IONS?
Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APLS or IONS?
Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 77.68x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 2.87x versus 13.95x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APLSApellis Pharmaceuticals, Inc.2.87x 77.68x $458.6M $215.7M IONSIonis Pharmaceuticals, Inc.13.95x -- $156.7M -$128.6M
-
Which has Higher Returns APLS or SRPT?
Sarepta Therapeutics, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of -45.06%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.
Company Gross Margin Earnings Per Share Invested Capital APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B -
What do Analysts Say About APLS or SRPT?
Apellis Pharmaceuticals, Inc. has a consensus price target of $33.95, signalling upside risk potential of 47.15%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 0.59%. Given that Apellis Pharmaceuticals, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Apellis Pharmaceuticals, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APLSApellis Pharmaceuticals, Inc.11 7 1 SRPTSarepta Therapeutics, Inc.7 14 3 -
Is APLS or SRPT More Risky?
Apellis Pharmaceuticals, Inc. has a beta of 0.305, which suggesting that the stock is 69.48% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.536%.
-
Which is a Better Dividend Stock APLS or SRPT?
Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APLS or SRPT?
Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are larger than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 77.68x while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 2.87x versus 0.91x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APLSApellis Pharmaceuticals, Inc.2.87x 77.68x $458.6M $215.7M SRPTSarepta Therapeutics, Inc.0.91x 20.50x $399.4M -$179.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
58
AAOI alert for Jan 29
Applied Optoelectronics, Inc. [AAOI] is down 16.38% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is down 1.35% over the past day.
Buy
93
ATEYY alert for Jan 29
Advantest Corp. [ATEYY] is down 9.48% over the past day.
